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The putative locus for hereditary mixed polyposis syndrome (HMPS) in a large family of Ashkenazi descent (SM96)
was previously reported to map to chromosome sub-bands 6q16–q21. However, new clinical data, together with
molecular data from additional family members, have shown 6q linkage to be incorrect. A high-density genomewide
screen for the HMPS gene was therefore performed on SM96, using stringent criteria for assignment of affection
status to minimize phenocopy rates. Significant evidence of linkage was found only on a region on chromosome
15q13-q14. Since this region encompassed CRAC1, a locus involved in inherited susceptibility to colorectal ade-
nomas and carcinomas in another Ashkenazi family (SM1311), we determined whether HMPS and CRAC1 might
be the same. We found that affected individuals from both families shared a haplotype between D15S1031 and
D15S118; the haplotype was rare in the general Ashkenazi population. A third informative family, SM2952, showed
linkage of disease to HMPS/CRAC1 and shared the putative ancestral haplotype, as did a further two families,
SMU and RF. Although there are probably multiple causes of the multiple colorectal adenoma and cancer phenotype
in Ashkenazim, an important one is the HMPS/CRAC1 locus on 15q13–q14.
Introduction
Hereditary mixed polyposis syndrome (HMPS [MIM
601228]) is characterized by the development of a va-
riety of different colorectal tumors (Whitelaw et al.
1997), including atypical juvenile polyps, hyperplastic
polyps with areas of dysplasia (serrated adenomas), clas-
sical adenomas, and carcinoma. In contrast to familial
adenomatous polyposis, disease in the only known
HMPS kindred (SM96) appears to be confined to the
large bowel. Most older individuals in SM96 presented
with colorectal carcinoma, whereas younger individuals
presented with polyps of either the atypical juvenile or
hyperplastic type, suggesting progression from hyper-
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plastic polyp to serrated adenoma to carcinoma. A sim-
ilar natural history has been shown in other disorders
characterized by the presence of polyps and increased
risk of malignancy, including juvenile polyposis syn-
drome (Woodford-Richens et al. 2000), Cowden syn-
drome (Marsh et al. 1998), and Peutz-Jeghers syndrome
(Gruber et al. 1998; Wang et al. 1999).
In family SM96, disease is inherited as an autosomal
dominant trait, and a previous study mapped theHMPS
locus to chromosome bands 6q16–q21 (Thomas et al.
1996). The HMPS gene was not identified. Over the 6
years since the HMPS locus was mapped to chromo-
some 6 (Thomas et al. 1996), one individual from SM96
without the putative disease-associated haplotype (pa-
tient 4.30) has developed multiple colorectal adenomas,
before the age of 40 years. These data strongly suggested
that the reported location of the putative HMPS gene
on chromosome 6 was incorrect. We have therefore re-
tested SM96 for linkage of disease to 6q16–q21, using
updated affection status and genetic markers from re-
cent genetic maps. We then undertook a new genome-
wide linkage screen in family SM96 with a high-density
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Figure 1 Pedigree of selected part of family SM96, showing haplotypes for the following chromosome 6 markers: D6S1716, D6S468,
D6S283, D6S434, D6S1580, D6S301, D6S1592, and D6S447. Black bars denote the haplotype that was previously thought to segregate with
disease. Known affected individuals are indicated by a blackened symbol. Inferred haplotypes are bracketed.
set of markers and a conservative assignment of affec-
tion status.
Subjects and Methods
Pedigree Collection and Assignment of Affection Status
The development of multiple adenomas by individual
4.30 led us to perform a systematic reassessment of the
affection statuses in family SM96. In such a large family,
a small number of phenocopies would be expected for
relatively common conditions such as a single colorectal
adenoma or carcinoma, or multiple hyperplastic polyps
of the rectum. We therefore used a relatively uncommon
and specific phenotype—multiple (3) colorectal ade-
nomas (including polyps with adenomatous areas)—as
the basis of our affection criteria. Updated pedigree in-
formation was obtained from members of SM96, and
patient information, histology reports, and samples were
obtained with full informed consent and ethical review
board approval. Importantly, all clinicopathological data
were reverified from histology reports, and unverified
data were excluded. Besides those classed as “affected,”
spouses marrying into the family were classed as “unaf-
fected,” and all other individuals, including those with
unverified clinicopathological data, were classed as of
“unknown” status. Furthermore, all individuals were
typed for the Ashkenazi-specificAPCI1307K variant, and
any carriers of this were classed as having unknown af-
fection status, since their disease might result from
I1307K, from the unknown gene, or from both. (In ad-
dition to some extra individuals included in this study,
the differences between the new and old affection statuses
can generally be assessed by comparing fig. 1 of Thomas
et al. [1996] with the results in this article.) In addition
to family SM96, we also ascertained and analyzed mem-
bers of family SM1311 and members of three other new
families, SM2592, SMU, and RF.
Exclusion of Chromosome 6q
Blood samples were obtained from 57 members of
SM96, who provided useful information for linkage anal-
ysis. DNA was extracted from either established cell lines
or blood, by use of standard methods. Polymorphic mi-
crosatellite markers D6S1716, D6S1580, and D6S1592,
spanning an interval of ∼8.5 cM and mapping to
6q16–q21, were chosen from The Genetic Location Da-
tabase. PCR amplification of these plus the original mark-
ers (Thomas et al. 1996) comprising the putative disease-
associated haplotype (D6S283, D6S434, and D6S301),
was performed. Reactions comprised 25 ng of genomic
DNA in 25-ml volumes, containing 1# standard PCR
buffer, 1.5 mM Mg2, 0.4 mM dNTPs, 0.25 U Taq poly-
merase, and 0.5 mM of each oligonucleotide primer. Each
forward primer was labeled with HEX, FAM, or TET.
Cycling conditions consisted of an initial denaturation of
94C for 5 min, followed by 35 cycles of 94C for 30 s,
55C for 30 s, and 72C for 30 s, with a final extension
step of 72C for 7 min. 0.2 ml of each PCR product was
combined with 0.2 ml of Tamra350 or Tamra500 size
standard (PE Applied Biosystems) and 3 ml of formamide
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Figure 3 Pedigree of family SM2592, showing haplotypes for the same chromosome 15 markers as are shown in figure 2. Symbols are
the same as in figure 1.
loading buffer. After denaturation at 94C for 5 min,
products were electrophoresed on 5% denaturing poly-
acrylamide gels on an ABI377 semiautomated sequencer
for 2 h. Results were analyzed by use of Genescan and
Genotyper software (Applied Biosystems).
Genomewide Linkage Analysis
PCR amplification of 387 microsatellite markers,
spaced at ∼10 cM intervals across the genome, was per-
formed on 57 individuals from SM96 by use of the We-
ber 9 set (Research Genetics). PCR and electrophoretic
conditions were as described for the chromosome 6
markers. For linkage analysis, HMPS was modeled as a
dominant trait ( ), with penetrancesqp 0.001 AAp
, , and . Two-point LOD0.75 Aap 0.75 aap 0.001
scores were calculated for each marker using the sub-
program MLINK (version 5.1) of the LINKAGE pro-
gram package (Lathrop et al. 1984), as implemented in
FASTLINK (version 4.1) (Cottingham et al. 1993). Mul-
tipoint analyses were undertaken using the VITESSE
program (O’Connell and Weeks 1995). Marker allele
frequencies were taken from The Genome Database or
from the genotyping of pedigree founders.
Typing of Markers on Chromosome 15q13–q14
In addition to marker ACTC from the genome screen,
the following additional markers close to ACTC were
typed in all five families, to refine the location of
the HMPS gene: (cenrtel) D15S1031, D15S1010,
D15S144, D15S995, D15S1007, D15S1040, ACTC,
D15S971, and D15S118. Two-point and multipoint
linkage analyses were undertaken by use of the same
affection criteria and model as for the SM96 genome
screen.
Loss of Heterozygosity (LOH) Analysis
DNA was extracted from archival paraffin-embedded
tumor tissue. The appropriate tissue was microdissected
by use of a sterile needle and was digested in 400 mg
proteinase K/ml and 1# Perkin Elmer PCR buffer (no
Mg2) at 55C. After digestion, the proteinase K was
heat denatured at 95C for 10 min. Samples were then
centrifuged at 13,000 rpm for 10 min, the supernatant
removed, and 2 ml used per PCR, using markers
D15S1010, D15S144, D15S995, D15S1007, ACTC,
and D15S1040. Allelic loss was only considered present
if the ratio of peak areas was either !0.5 or 12.0, after
correction for the relative areas in constitutional DNA.
Results
SM96 family members were genotyped at the three orig-
inal polymorphic markers (Thomas et al. 1996) and
three newmarkers close to the reported site of theHMPS
locus at 6q16–q21. These data were used for two-point
and multipoint LOD-score analysis using the revised af-
fection criteria. LOD scores throughout the region were
uniformly negative and were sufficient to exclude the
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Table 1
Two-Point LOD Scores for 15q13–14 Markers, Using Combined
Genotyping Data from Families SM96, SM1311, and SM2952
MARKER
AND
FAMILY
LOD AT RECOMBINATION FRACTION
APPROXIMATE
CHROMOSOME
15 MAP
POSITION
(cM).001 .101 .201 .301 .401
D15S1031: 1.28 2.04 1.61 1.02 .41 26.0
SM96 2.54 2.11 1.59 1.00 .041
SM1311 1.50 .22 .06 .01 .01
SM2592 .23 .15 .08 .03 .01
D15S1010: 3.48 2.65 1.83 1.05 .37 28.2
SM96 2.29 1.79 1.26 .71 .22
SM1311 1.01 .75 .51 .31 .14
SM2592 .18 .11 .06 .02 .01
D15S144: 1.83 1.49 1.15 .81 .42 28.7
SM96 1.91 1.56 1.21 .83 .42
SM1311 .09 .08 .06 .03 .00
SM2592 .02 .01 .00 .00 .00
D15S995: 3.08 2.29 1.49 .73 .16 28.8
SM96 2.32 1.76 1.17 .58 .12
SM1311 .42 .30 .19 .10 .03
SM2592 .34 .22 .12 .05 .01
D15S1007: 1.51 1.07 1.15 .86 .37 28.9
SM96 3.35 2.73 2.05 1.31 .55
SM1311 2.08 1.80 .98 .49 .19
SM2592 .24 .15 .08 .03 .01
D15S1040: 3.09 2.37 1.71 1.12 .56 29.3
SM96 2.35 1.93 1.49 1.02 .52
SM1311 .68 .41 .21 .09 .04
SM2592 .06 .03 .02 .01 .00
ACTC: 5.31 4.22 3.10 1.97 .87 30.4
SM96 3.98 3.25 2.47 1.63 .74
SM1311 1.19 .88 .58 .32 .13
SM2592 .14 .08 .04 .02 .00
D15S971: 1.45 2.21 1.68 1.01 .33 30.7
SM96 .62 1.61 1.29 .79 .24
SM1311 .77 .57 .38 .21 .08
SM2592 .06 .04 .02 .01 .00
D15S118: .85 1.55 1.33 .87 .36 31.0
SM96 1.21 1.32 1.20 .82 .35
SM1311 .00 .00 .00 .00 .00
SM2592 .36 .23 .13 .05 .01
NOTE.—The maximum LOD score obtained was 5.31, for ACTC.
putativeHMPS susceptibility gene from this region (data
not shown). Haplotype construction confirmed that dis-
ease and 6q16–q21 alleles did not cosegregate (fig. 1).
The previously presumed phenocopy (individual 4.30)—
who had a single adenoma but has since developed four
adenomas—was confirmed as not carrying the putative
“linked” haplotype. Moreover, typing of additional
markers revealed that one other individual (4.6) had
developed adenomas without carrying the linked hap-
lotype, although this individual was found to carry the
APCI1307K variant.
The new genomewide screen on family SM96 re-
vealed only one site in the genome with good evidence
of linkage to HMPS. This region was on chromosome
15q13–q21, close to marker ACTC. A maximum two-
point LOD score of 3.98 was found at ACTC and a
maximummultipoint LOD score of 4.67 was also found
at ACTC. Further markers mapping to this region were
chosen to give a dense haplotype in an attempt to define
the minimal region containing the disease gene. Hap-
lotype construction showed the minimal region con-
taining the HMPS gene to lie between D15S1031 and
D15S118, a 10-cM interval (fig. 2). The HMPS gene
was shown to be highly penetrant: of 20 individuals in
SM96 sharing the haplotype, 18 were affected.
There are two main explanations as to why 15q link-
age was not found in SM96 by the initial genome screen.
First, some individuals whom we previously classed as
affected were reclassified as “unknown,” because the
original data provided by the patient could not be con-
firmed from histopathological records (for example, pa-
tients 3.70, 3.80, 3.90, and the entire nuclear family of
patient 3.1 [see fig. 1 fromThomas et al. 1996]). Second,
some individuals were reclassified as “unknown” be-
cause they had colorectal tumor(s) but not multiple ad-
enomas. Patient 3.9 and his nuclear family are good
examples. He was screened for colorectal tumors in his
50s and was reassured that he had not inherited the
family’s predisposition to polyps. He subsequently de-
veloped an isolated colorectal carcinoma at age 63
years, but there was still no evidence of the specific
HMPS phenotype. To date, none of his four children
has developed any adenoma, although his daughter
(4.11) had previously reported that she had hadmultiple
polyps and had been classed as affected; on subsequent
investigation, the “polyps” turned out to be ulcerative
colitis. It is most likely, therefore, that patient 3.9’s can-
cer was “sporadic” and unrelated to an inherited sus-
ceptibility. Although allowance was made for such phe-
nocopies in the calculation of LOD scores in the
previous genome screen, this did not prevent incorrect
assignment of the HMPS locus to chromosome 6. Our
revised strategy of relying on individuals with a distinct
phenotype to provide linkage information proved to be
more prudent.
A genomewide screen previously performedonanother
Ashkenazi family (SM1311) had mapped a new colorec-
tal tumor susceptibility gene, CRAC1, to 15q14–q22
(Tomlinson et al. 1999). The linked haplotype had
spanned a 40-cM interval defined by D15S1031 and
D15S153, a larger region than that found for SM96. We
wonderedwhetherHMPS andCRAC1might be the same
locus. When the CRAC1 and SM96 disease-associated
haplotypes were compared, we found that they were
identical for markers shared within the HMPS region
(D15S1031–D15S118). Following this discovery, we ex-
amined an additional Ashkenazi family (SM2952) with
multiple colorectal adenomas. No serrated adenomas or
dysplastic hyperplastic polyps had been diagnosed in this
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Figure 4 A sliding map of three markers was used to calculate multipoint linkage analysis between markers D15S1031 and D15S118.
Combined genotyping data from families SM96, SM1311, and SM2592 were used.
family, although not all histopathologists use this clas-
sification. Typing of markers D15S1031 to D15S118 at
15q13–q14 in this family showed that all affected mem-
bers shared theminimalHMPS/CRAC1 regionhaplotype
(fig. 3).
By use of combined genotyping data for markers
D15S1031 to D15S118 from families SM96, SM1311,
and SM2952, further two-point and multipoint LOD
score analyses were performed. By use of the affection
criteria adopted for this study (and incorporating a
small amount of updated clinical information for
SM1311), maximum two-point and multipoint LOD
scores of 5.31 and 7.19, respectively, were obtained at
marker ACTC (table 1 and fig. 4) for the three families
combined.
We then ascertained a further two Ashkenazi kin-
dreds, one with a history of multiple colorectal ade-
nomas and cancer (SMU) and one with mixed hyper-
plastic/adenomatous polyps (RF). Although these fam-
ilies were not informative for linkage analysis, all four
affected individuals typed carried the minimal HMPS
haplotype between D15S1031 and D15S118. We sub-
sequently found that the disease-associated haplotype
was not present in any spouse marrying into the families
studied (figs. 2 and 3) and was present in, at most, 1
of 95 random Ashkenazi controls (although haplotypes
could not be assigned for the latter).
To investigate the possibility that the HMPS/CRAC1
gene might act as a tumor suppressor, LOH analysis
was performed on 22 colorectal tumors from two SM96
and five SM1311 family members, by use of a selection
of microsatellite markers. Only two tumors (from the
same SM1311 member) showed loss of the wild-type
allele, each with all five markers used. These data sup-
ported those reported previously (Tomlinson et al.
1999), in that limited LOH was observed. The reasons
for the low frequency of LOH—for example, dominant
germline mutation, haploinsufficiency, or “second hit”
by promoter methylation—are currently unclear.
Discussion
We have shown that the HMPS gene is not located at
6q16–61, as previously reported, but at 15q13–q14.
Furthermore, analysis of the 15q haplotypes of families
SM96, SM1311, and SM2952, together with the sig-
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nificant LOD scores from two-point and multipoint
analyses, shows that the region containing the HMPS
gene overlaps that containing the CRAC1 gene. Com-
parison of data derived from the five families (SM96,
SM1311, SM2952, SMU, and RF) revealed that all af-
fected individuals who were tested shared the same hap-
lotype in this region. The CRAC1 gene is therefore
highly likely to be identical to the HMPS gene. The
shared haplotype is therefore most probably derived
from a common founder. Although the precise origin of
families SM1311, SM2592, and RF are unknown, fam-
ilies SM96 and SMU originate from Lithuania, which is
consistent with recent common ancestry.
The phenotypes of the five families are very similar,
with members having developed multiple, classical co-
lorectal adenomas and carcinomas (Tomlinson et al.
1999). Members of SM96, SM1311, and RF have also
developed early-onset tumors which have features of
both ‘classical’ adenomas and hyperplastic polyps, re-
ferred to variously as “dysplastic hyperplastic polyps,”
“mixed hyperplastic/adenomatous polyps,” or “ser-
rated adenomas.” No member of SM1311, SM2952,
SMU, or RF has been reported as developing the atyp-
ical juvenile polyps reported to occur in a few members
of SM96 (Whitelaw et al. 1997).
Together, these data provide compelling evidence for
a high-penetrance colorectal tumor predisposition gene,
HMPS/CRAC1, at 15q13–q14. This region contains
few good candidate genes, a small number of genes with
known function, and several predicted genes/proteins.
HMPS/CRAC1may explain some of the increased pop-
ulation prevalence of colorectal tumors in the Ashkenazi
population. Although the multiple adenoma phenotype
in this group may also result from mutations in APC,
MYH, and other uncharacterized genes, all five multiple
adenoma families which we have typed (and fromwhich
APC mutations have been excluded) probably result
from HMPS/CRAC1 mutations. It remains to be seen
whether HMPS/CRAC1 is also important in other eth-
nic groups.
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